# breast cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 7
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 54784
- Completion tokens: 22386
- Reasoning tokens: 0
- Total tokens: 77170
- API requests reported: 4
- Elapsed seconds: 231.01
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 5/5; original repeat 7; model vendor: OpenAI

---
## Data-quality and evidentiary qualification

The ledger contains **100 unique genes from 106 retained rows**, including **6 duplicated gene/probe rows**. All 100 genes meet **P ≤ 0.05 and FDR ≤ 0.05**, with 52 risk-associated genes and 48 protective-associated genes. The very broad separation and uniformly extreme significance values—FDR values from **4.4762322e-10 to 1.7414147e-06**—should be treated cautiously, particularly if the genes were preselected, if the survival model was not independently tested, or if expression and outcome data were used during feature selection.

The uploaded HR values are the only direct statistical evidence. **External statistical validation was not performed**: no independent-cohort HR, P value, FDR, cohort, endpoint definition, or model was supplied. The pathway, STRING, tissue, disease, therapeutic, and literature records therefore provide biological context, not replication or new significance testing.

## 1. Overall biological interpretation

The dominant prognostic pattern is a contrast between:

1. A broad **mitotic and cell-cycle program associated with higher mortality risk**, including PKMYT1, RACGAP1, KIF20A, TROAP, CDCA5, TPX2, KIF4A, UHRF1, UBE2C, PTTG1, CDC20, AURKA, ZWINT, NUSAP1, UBE2S, and PRC1.
2. A smaller but coherent **immune, stromal, epithelial-differentiation, and extracellular-matrix program associated with lower mortality risk**, including FCER1A, JCHAIN, STAT5A/STAT5B, CD1C, CD1E, KLRB1, OGN, COL14A1, MFAP4, LAMA2, ADAMTS8, COL17A1, and IGF1.
3. Additional risk-associated signals involving **translation/proteostasis, cytoskeletal organization, metabolism, and stress adaptation**, represented by LARP1, STIP1, GSK3B, EZR, CPT1A, ATP2A2, and TRIB3.

The most defensible interpretation is that the risk-associated component reflects tumors with greater proliferative and mitotic activity, while the protective-associated component may reflect immune infiltration, preserved epithelial/stromal differentiation, or tumor composition rather than protective activity of each individual gene. These are prognostic associations, not demonstrations that any gene causes poor or improved survival.

## 2. Core biological programs

### Program 1 — Mitotic cell cycle, chromosome segregation, and proliferation

- **Association:** Higher mortality risk.
- **Supporting genes:** PKMYT1 (HR=1.2437685), RACGAP1 (HR=1.223506), KIF20A (HR=1.2180492), CDCA5 (HR=1.2179013), TPX2 (HR=1.2017253), UBE2C (HR=1.2100353), CDC20 (HR=1.1912581), AURKA (HR=1.1885146), NUSAP1 (HR=1.1942371), and PRC1 (HR=1.1859845).
- **Relevant pathways:** **KEGG Cell cycle**; GO: **positive regulation of mitotic nuclear division (GO:0045840)**; Hallmark **E2F targets**, **G2M checkpoint**, and **mitotic spindle**, where applicable.
- **Interpretation:** Multiple genes spanning mitotic entry, spindle assembly, cytokinesis, chromosome movement, and APC/C-mediated cell-cycle progression show concordant HR>1. The signal is therefore program-level rather than driven by a single canonical proliferation marker.
- **Evidence strength:** Strongest direct pattern in the dataset; supported by pathway annotations and STRING-associated network records involving TPX2, AURKA, KIF20A, CDC20, NUSAP1, and PRC1.
- **Limitations:** The supplied pathway recurrence is annotation evidence rather than a newly calculated enrichment P value. Proliferation may be a surrogate for tumor grade, stage, subtype, treatment resistance, or tumor purity. The STRING records do not establish that every listed gene physically interacts.

### Program 2 — APC/C-dependent ubiquitination and proteolytic cell-cycle control

- **Association:** Higher mortality risk.
- **Supporting genes:** UBE2C (HR=1.2100353; FDR=1.7306539e-07), UBE2S (HR=1.1841829), CDC20 (HR=1.1912581), PTTG1 (HR=1.1974445), and related network genes including ANAPC2.
- **Relevant pathways:** Reactome **APC/C:Cdc20-mediated degradation of Cyclin B**, **degradation of Securin**, and GO **ubiquitin-protein transferase activity** and **protein polyubiquitination**.
- **Interpretation:** This module is mechanistically related to mitotic progression but is sufficiently specific to distinguish ubiquitin-dependent checkpoint release from general proliferation. UBE2C and UBE2S are ubiquitin-conjugating enzymes, while CDC20 provides APC/C cofactor activity; their joint risk association is consistent with increased cell-cycle turnover.
- **Evidence strength:** Direct concordance among several risk-associated genes, with Reactome and QuickGO support. The retrieved STRING record links CDC20, UBE2C, UBE2S, and ANAPC2 at the network level.
- **Limitations:** These genes may largely represent the same underlying proliferation signal, so they should not be treated as independent prognostic mechanisms. The available evidence does not show that APC/C activity itself was measured.

### Program 3 — Immune-cell and antigen-presentation-associated state

- **Association:** Lower mortality risk.
- **Supporting genes:** FCER1A (HR=0.7932319), CD1C (HR=0.81422548), CD1E (HR=0.82361278), KLRB1 (HR=0.82162453), STAT5A (HR=0.80627148), STAT5B (HR=0.83716163), IL27RA (HR=0.82546531), FLT3 (HR=0.81703284), and JCHAIN (HR=0.80290118).
- **Relevant pathways:** GO terms involving **antigen processing/presentation**, immune-cell differentiation, and cytokine signaling; Reactome immune-system pathways would be appropriate for formal testing, but no new enrichment analysis was performed here.
- **Interpretation:** CD1C, CD1E, and FCER1A are compatible with dendritic-cell or antigen-presenting-cell content, while KLRB1 and the STAT5 genes are compatible with lymphoid/cytokine-related immune states. JCHAIN may indicate immunoglobulin-producing cell content. Their consistent HR<1 suggests that an immune-rich tumor microenvironment may be associated with better OS in this cohort.
- **Evidence strength:** Coherent direct prognostic association across multiple immune-related genes, supported by tissue-expression and disease annotations. The literature record for PROS1 also connects a protective-associated gene in this dataset to immune infiltration and prognosis in breast cancer (PMID: **37827342**), although PROS1 is not evidence of independent validation of this full module.
- **Limitations:** This is particularly vulnerable to differences in immune-cell composition. The data do not establish antitumor immune function, cellular localization, or causal immune protection. The apparent signal could reflect stromal/immune abundance, treatment selection, or subtype composition.

### Program 4 — Extracellular matrix, stromal structure, and epithelial differentiation

- **Association:** Lower mortality risk.
- **Supporting genes:** OGN (HR=0.80743973), COL14A1 (HR=0.82355765), MFAP4 (HR=0.83417958), LAMA2 (HR=0.83003966), ADAMTS8 (HR=0.7928718), COL17A1 (HR=0.79759519), PDGFRA (HR=0.83760447), RELN (HR=0.79635886), and CLDN11 (HR=0.81928027).
- **Relevant pathways:** GO **extracellular region**, **extracellular matrix organization**, and **cell-substrate adhesion**; Reactome extracellular-matrix organization.
- **Interpretation:** The joint protective association of matrix-associated genes and epithelial-structural genes is compatible with preserved stromal organization, basement-membrane features, or a less dedifferentiated tumor state. However, this may also be a composition signal from fibroblasts, normal epithelium, or other nonmalignant cells.
- **Evidence strength:** Multi-gene direct association and consistent extracellular-region annotations. MFAP4, OGN, COL14A1, LAMA2, and ADAMTS8 provide convergent matrix-related support rather than reliance on one gene.
- **Limitations:** No tumor-purity adjustment, cell deconvolution, spatial data, or protein localization was supplied. Matrix abundance is not equivalent to a tumor-suppressive matrix function.

### Program 5 — Translation, metabolic adaptation, and stress/cytoskeletal regulation

- **Association:** Predominantly higher risk, with some protective-associated metabolic genes.
- **Supporting genes:** LARP1 (HR=1.2611983), STIP1 (HR=1.2368966), GSK3B (HR=1.2271421), EZR (HR=1.2269146), ATP2A2 (HR=1.2378678), CPT1A (HR=1.1962357), GPRC5A (HR=1.2018529), and TRIB3 (HR=1.1914433). Protective-associated metabolic or redox genes include IGF1 (HR=0.80347674), GSTK1 (HR=0.83669729), and AK3 (HR=0.81374648).
- **Relevant pathways:** GO **RNA binding**, **ATP binding**, glutathione metabolism, fatty-acid oxidation, proteostasis, and cytoskeletal organization; Reactome annotations include **glutathione conjugation** for GSTK1.
- **Interpretation:** This mixed program may represent increased biosynthetic demand, altered energy use, protein-folding or stress responses, and motility-related cytoskeletal remodeling. Because risk and protective directions are mixed, it is less coherent than the mitotic program and should not be interpreted as a single confirmed metabolic pathway.
- **Evidence strength:** Direct associations and pathway plausibility; STIP1 has been reported in a pan-cancer prognosis/immune-infiltration analysis (PMID: **37488801**), and GPRC5A has been proposed as a cancer biomarker in another disease context (PMID: **40865843**).
- **Limitations:** These literature records are not breast-cancer independent validation and may reflect different endpoints or tumor types. The current data do not distinguish tumor-cell metabolism from stromal or immune metabolism.

## 3. Key genes and interaction modules

| Candidate | Current association | Program relevance | Relationship type and interpretation |
|---|---:|---|---|
| **PKMYT1–AURKA–TPX2–KIF20A–NUSAP1/PRC1 module** | Risk-associated; e.g. PKMYT1 HR=1.2437685, AURKA HR=1.1885146, TPX2 HR=1.2017253 | Mitotic entry, spindle assembly, chromosome segregation, cytokinesis | **Pathway co-membership and network association**. STRING records connect portions of this module, but the supplied evidence does not establish direct physical interaction for every pair. |
| **CDC20–UBE2C–UBE2S module** | Risk-associated; CDC20 HR=1.1912581, UBE2C HR=1.2100353, UBE2S HR=1.1841829 | APC/C-dependent ubiquitination and mitotic exit | **Regulatory/functional pathway relationship** through APC/C biology; Reactome supports the pathway. It is not evidence that all three proteins directly bind one another. |
| **LARP1** | Risk-associated, HR=1.2611983, P=2.0894516e-14, FDR=4.4762322e-10 | RNA translation and growth-related biosynthetic demand | **Functional annotation and indirect/putative relationship** to the proliferative state; no direct interaction with the mitotic genes is established here. |
| **STIP1** | Risk-associated, HR=1.2368966, FDR=9.7437879e-10 | Proteostasis, stress response, tumor–immune context | **Literature association and possible co-expression**, not a demonstrated causal regulator in this dataset. Breast-cancer relevance is suggested by PMID **37488801**, but external statistical validation was not performed. |
| **GSK3B–WNT7B axis** | Both risk-associated: GSK3B HR=1.2271421; WNT7B HR=1.1834371 | Signaling, differentiation, and potentially growth control | **Putative pathway relationship**; the supplied results do not demonstrate direct regulation, pathway activation, or causal WNT signaling. |
| **CPT1A** | Risk-associated, HR=1.1962357, FDR=2.2486068e-08 | Fatty-acid utilization and metabolic adaptation | **Pathway co-membership/functional plausibility**, not evidence of a direct interaction with proliferation genes or of causal metabolic dependence. |
| **FCER1A–CD1C–CD1E module** | Protective-associated; FCER1A HR=0.7932319, CD1C HR=0.81422548, CD1E HR=0.82361278 | Antigen-presenting-cell-associated tumor microenvironment | **Cell-type co-expression and pathway co-membership** are the most likely relationship types. This may reflect infiltrating dendritic cells rather than tumor-cell expression. |
| **STAT5A–STAT5B–IL27RA module** | Protective-associated; STAT5A HR=0.80627148, STAT5B HR=0.83716163, IL27RA HR=0.82546531 | Cytokine-responsive immune state | **Regulatory/pathway relationship is plausible**, but direct transcriptional regulation or activation was not demonstrated in the supplied records. |
| **OGN–COL14A1–MFAP4–LAMA2 module** | Protective-associated; OGN HR=0.80743973, COL14A1 HR=0.82355765, MFAP4 HR=0.83417958 | ECM and stromal organization | **Extracellular-matrix co-membership and possible co-expression**, not a direct physical interaction claim. |
| **PROS1** | Protective-associated, HR=0.83621827, FDR=1.0775537e-06 | Immune infiltration and possible tumor-suppressive context | **Literature-supported disease association**, not causal evidence. PMID **37827342** reports a breast-cancer prognostic and immune-infiltration association, but does not constitute independent validation of this dataset’s HR. |

## 4. Validation priorities

### 1. Validate the proliferation/APC-C risk program  
- **Class:** Biomarker and mechanistic hypothesis.
- **Why prioritize:** It is the most internally coherent signal, with numerous risk-associated genes spanning mitosis, spindle function, and APC/C ubiquitination.
- **Current evidence:** Strong direct association: examples include PKMYT1 HR=1.2437685, UBE2C HR=1.2100353, AURKA HR=1.1885146, and CDC20 HR=1.1912581, all with FDR<\(10^{-6}\).
- **External evidence:** GO/Reactome/KEGG and STRING support the biological relationships. These are contextual annotations, not replication.
- **Next step:** Test a prespecified proliferation score in an independent breast-cancer OS cohort, adjusted for stage, grade, molecular subtype, treatment, and age; then measure Ki-67, phospho-histone H3, and mitotic indices in matched tissue.
- **Conclusion level:** **Supported hypothesis**, not established prognostic validation.

### 2. Determine whether the protective immune signal reflects immune composition or active antitumor immunity  
- **Class:** Confounding or composition check and biomarker.
- **Why prioritize:** FCER1A, CD1C, CD1E, KLRB1, STAT5A/B, FLT3, and JCHAIN are concordantly protective-associated, but many are plausibly cell-type markers.
- **Current evidence:** Direct HR<1 associations, including FCER1A HR=0.7932319 and CD1C HR=0.81422548.
- **External evidence:** Tissue and immune annotations support cellular plausibility; PROS1 literature links prognosis with immune infiltration in breast cancer (PMID **37827342**). This does not establish that the immune cells are functionally protective.
- **Next step:** Apply bulk RNA deconvolution and tumor-purity adjustment, followed by single-cell or spatial RNA-seq and immunohistochemistry for dendritic cells, lymphocytes, plasma cells, and tumor cells.
- **Conclusion level:** **Supported hypothesis** for an immune-rich state; the causal immune mechanism remains an **exploratory hypothesis**.

### 3. Test the ECM/stromal differentiation program independently of tumor purity  
- **Class:** Biomarker and confounding/composition check.
- **Why prioritize:** OGN, COL14A1, MFAP4, LAMA2, ADAMTS8, and related genes form a coherent protective-associated structural signature.
- **Current evidence:** Multiple HR<1 values, including ADAMTS8 HR=0.7928718 and COL14A1 HR=0.82355765.
- **External evidence:** Extracellular-region and matrix annotations support plausibility, but no independent cohort statistic was supplied.
- **Next step:** Quantify stromal and epithelial compartments histologically, compare the signature with fibroblast and normal-epithelium markers, and validate protein localization by multiplex immunohistochemistry or spatial transcriptomics.
- **Conclusion level:** **Supported hypothesis**, with substantial potential for composition confounding.

### 4. Evaluate LARP1/STIP1 and metabolic adaptation as a secondary prognostic axis  
- **Class:** Mechanistic hypothesis and biomarker.
- **Why prioritize:** LARP1 and STIP1 are among the strongest risk-associated genes, while CPT1A, GSK3B, EZR, and ATP2A2 suggest biosynthetic, signaling, metabolic, and cytoskeletal adaptation.
- **Current evidence:** LARP1 HR=1.2611983 and STIP1 HR=1.2368966; CPT1A HR=1.1962357 and GSK3B HR=1.2271421.
- **External evidence:** STIP1 prognosis/immune-infiltration literature exists (PMID **37488801**), and GPRC5A has been proposed as a biomarker in gastric cancer (PMID **40865843**), but these are not breast-cancer replication statistics.
- **Next step:** Validate protein abundance and pathway activity, measure lipid oxidation and translation-related phenotypes in breast-cancer models, and test whether associations persist after adjustment for proliferation.
- **Conclusion level:** **Exploratory hypothesis**, because these genes may be passengers or correlated with the dominant proliferation program.

### 5. Test whether the mitotic genes form a functionally connected network rather than a correlated expression signature  
- **Class:** Interaction/network hypothesis.
- **Why prioritize:** Retrieved STRING records identify recurrent associations involving PLK1, TPX2, CDC20, ANAPC2, BUB1B, and DLGAP5.
- **Current evidence:** Multiple genes in the network are risk-associated, including AURKA, CDC20, KIF20A, UBE2C, TPX2, NUSAP1, and PRC1.
- **External evidence:** STRING and Reactome support functional or database-level relationships; STRING evidence may combine physical interaction, curated knowledge, co-expression, and prediction and should not be interpreted uniformly as direct binding.
- **Next step:** Use co-immunoprecipitation or proximity assays for selected protein pairs, perturb one node at a time by CRISPR or pharmacology, and measure mitotic progression and survival-related phenotypes.
- **Conclusion level:** **Supported hypothesis** for network-level coherence; direct interaction for individual pairs is **insufficient evidence** unless experimentally demonstrated.

## 5. Major limitations and alternative explanations

1. **Potential statistical or selection bias:** The uniformly significant results and narrow HR range across all 100 genes are unusual. Reanalysis should document the original feature-selection procedure, censoring, proportional-hazards assumptions, missingness, multiple-testing procedure, and whether selection and validation used separate samples.

2. **No independent-cohort validation:** The external evidence pack contains annotations and literature but no independent OS statistic. Pathway recurrence, STRING edges, and published associations are not replication.

3. **Tumor purity and cell composition:** Protective immune and stromal genes may reflect infiltrating immune cells, fibroblasts, vessels, or normal epithelium. Purity estimates, immune deconvolution, pathology review, single-cell data, and spatial localization are needed to distinguish composition from tumor-cell biology.

4. **Clinical confounding:** Stage, grade, molecular subtype, age, treatment exposure, and recurrence risk can influence both gene expression and OS. Multivariable and stratified survival analyses are required before interpreting the signatures as subtype-independent prognostic factors.

5. **Association versus causation and pathway redundancy:** The mitotic genes may be highly correlated and reflect one latent proliferation variable. Pharmacological sensitivity or a drug record would not by itself establish therapeutic efficacy; causal claims require perturbation experiments and clinically relevant validation.

Overall, the most robust exploratory interpretation is a **high-proliferation, mitosis/APC-C-associated risk state contrasted with immune- and ECM-associated protective signatures**, while the independent prognostic validity, cellular source, and causal mechanisms remain to be established.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=83, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
